Furthermore, ARG2 deletion in CD8+ T cells has a considerable synergistic effect with PD-1 blockade in controlling tumour growth and animal survival, strongly suggesting that ARG2 is a valuable target for T cell-based cancer immunotherapies. This evidence concerns the gene CD8A and cancer.